Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Semaglutide is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type ... $81.1 million in the previous quarter. New drugs Omvoh and Ebglyss recorded sales of $20.4 million and ...

Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of ...

Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to ...

The company adds that the midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals ...

The midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for ...

One of the best things about compounded semaglutide (besides the accessible price) is that it typically comes in vials rather than prefilled injection pens. This gives healthcare providers a lot ...

in adults with obesity and FDA approval for Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. The company also noted its pending $2.5 billion acquisition of ...

The Nintendo Switch 2 is real. Finally, after months of rumors and speculation (and a recent flurry of leaks), Nintendo has confirmed one of the worst-kept secrets in gaming, its next console is a ...

Lyall Cameron has signed a pre-contract agreement at Rangers ahead of a summer move from Dundee. Record Sport first broke the news in January that the Ibrox side had rekindled their interest in ...

Then, in January, the FDA approved the company's drug Omvoh for Crohn's disease. The drug was first approved in October 2023 for patients with moderately to severely active ulcerative colitis ...